Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

467 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the investigators are interested to know if lower doses of Primaquine together with dihydroartemisinin-piperaquine can produce a similar effect of clearing both sexual and asexual parasites in asymptomatic carriers compared to the recommended dose of primaquine but with a decreased risk of haemolysis.

Children (\> 1 year) and adults with normal Glucose-6-phosphate dehydrogenase enzyme levels but with asexual Plasmodium falciparum parasites on the day of screening will be invited to take part in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes

NCT02090036

Plasmodium Falciparum

COMPLETED PHASE4

Low Dose Primaquine for Clearance of Gametocytes

NCT01935882

Malaria Asymptomatic Malaria Plasmodium Falciparum

COMPLETED PHASE2/PHASE3

Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia

NCT02654730

Malaria

TERMINATED PHASE2/PHASE3

Phase2a Primaquine Dose Escalation Study

NCT01743820

Malaria

COMPLETED PHASE2

Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission

NCT02259426

Malaria Asymptomatic Malaria Plasmodium Falciparum

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date, primaquine (PQ), an 8-aminoquinoline, is the only currently registered product able to clear P. falciparum mature gametocytes. However, its use has been and is still limited by its haematological toxicity (haemolytic anaemia), particularly but not exclusively in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PDd), in whom haemolysis can occur after a single PQ dose. Such an effect is dose-dependent. Considering that the current recommended dose was established several decades ago on a small number of experimentally challenged volunteers, it may be possible to obtain the same effect with a lower dose and hence decrease the risk of haemolysis. The proposed study is a four-arm, open label, randomized, controlled trial. G6PD-normal asymptomatic P. falciparum infected individuals identified through population screening will be randomized to receive either a complete course of dihydroartemisinin-piperaquine (DHA-PPQ) alone (control arm) or a complete course of DHA-PPQ plus a single dose of PQ at 3 differing dose strengths (intervention arms), i.e. 0.75mg/kg, 0.4mg base/kg and 0.2mg base/kg.

The study is planned to enroll 1,200 individuals with an asymptomatic malaria infection during the rainy /transmission season (June - December) from villages around the MRC's field stations at Walikunda and Basse in The Gambia. Asymptomatic parasite carriers identified by qualitative (RDT) and quantitative (parasites counts \>20/µl by slide microscopy) methods during population screening exercises at the villages will be invited for a written informed consent and further screening to confirm eligibility, including tests for qualitative G6PD enzyme function (fluorescence spot test) and haemoglobin. If eligible, they will be assigned to one of four study arms using a block randomization scheme in a 1:1:1:1 ratio ensuring a balance in enrollment between the four groups. Enrolled participants will receive ACT treatment on days 0, 1 and 2. On day 2, participants allocated to the PQ arms will receive a dose of primaquine based on determined body weight.

Each participant involvement consists of a maximum of 11 visits over a 42 day period after initiation of treatment. The primary end point is the prevalence of P. falciparum gametocyte carriers at day 7, as determined by QT-NASBA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eurartesim (control)

All participants will receive a complete course of DHA-PPQ (Eurartesim)

Group Type OTHER

DHA-PPQ

Intervention Type DRUG

Participants will receive a 3 day course of DHA-PPQ

Primaquine 0.75mg base/kg

Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight

Group Type EXPERIMENTAL

DHA-PPQ

Intervention Type DRUG

Participants will receive a 3 day course of DHA-PPQ

PQ (0.75)

Intervention Type DRUG

Participants will receive a single dose of PQ at 0.75mg base/kg body weight

Primaquine 0.4mg base /kg

Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight

Group Type EXPERIMENTAL

DHA-PPQ

Intervention Type DRUG

Participants will receive a 3 day course of DHA-PPQ

PQ (0.4)

Intervention Type DRUG

Participants will receive a single dose of PQ at 0.4mg base/kg body weight

Primaquine 0.2mg base/kg

Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight

Group Type EXPERIMENTAL

DHA-PPQ

Intervention Type DRUG

Participants will receive a 3 day course of DHA-PPQ

PQ (0.2)

Intervention Type DRUG

Participants will receive a single dose of PQ at 0.2mg base/kg body weight

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DHA-PPQ

Participants will receive a 3 day course of DHA-PPQ

Intervention Type DRUG

PQ (0.75)

Participants will receive a single dose of PQ at 0.75mg base/kg body weight

Intervention Type DRUG

PQ (0.4)

Participants will receive a single dose of PQ at 0.4mg base/kg body weight

Intervention Type DRUG

PQ (0.2)

Participants will receive a single dose of PQ at 0.2mg base/kg body weight

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Eurartesim Primaquine Primaquine Primaquine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age ≥1 year

* Weight \>10 Kg
* P. falciparum mono-infection, density of at least 20 parasites/μL
* Axillary temperature \< 37.5ºC
* Resident in the study area and willingness to reside for the duration of the study
* Written informed consent (plus an assent in children \>12years of age)

Exclusion Criteria

* G6PD Deficiency Haemoglobin \<8g/dl

* Known allergy to any of the study medications
* Known Pregnancy or breastfeeding
* Clear/documented history of anti-malarial treatment 2 weeks before contact with study team
* History of blood transfusion in the previous 3 months
* Any chronic or acute conditions that might interfere with the study as judged by the research clinician
* History of sickle cell anaemia

Minimum Eligible Age

12 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes